Avenir Global has appointed Miranda Dini as global healthcare lead, adding to her ongoing leadership of the communications firm’s Axon business in Europe.
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.